Developing novel treatments for mental health via psychedelic therapies...

Woke Pharmaceuticals is on a mission to change the status quo in the treatment of mental health.

Woke is focused on working with leading universities and research institutes to develop psychedelic therapies to help those who struggle with mental health.

We are committed to Innovation

In addition to developing proprietary synthetic psilocybin formulations, we are pioneering novel drug discovery.

To improve patients' psychedelic experience, we are developing dosing and delivery methods for psychedelics.

The company is pursuing global patents at every opportunity, with a foundational provisional patent application already filed and many more on the way.

Latest Announcements


December 2022 Corporate Presentation

Read More

Biotech Daily: Dr Boreham's Crucible on Woke

Read More
Press Release

Woke and University of Sydney Sign Term Sheet for Phase II trial of WP002 Psilocybin in Alcohol Use Disorder

Read More

Woke setting sights on Australian IPO in 2023

Read More

Research & Development

Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property

CandidateMoleculeDeliveryIndicationDevelopment StatusPartners
WP001Psilocybin (low dose)Rapid release CapsuleModerate DepressionEthics approval for Phase IIB trial in progress Macquarie University
WP002Psilocybin (high dose)Rapid release TabletTreatment-Resistent DepressionEthics submission for Phase IIB trial in November 2022 Imperial College London Drug Science (UK) Swinburne University
WP002Psilocybin (high dose)Rapid release TabletProlonged griefEthics submission for feasibility trial in November 2022 QIMR-Berghofer
WP002Psilocybin (high dose)Rapid release TabletAlcohol use disorderEthics submission for Phase II trial in Q1 CY2023 University of Sydney
WP003LSD (novel analogue)EnhancedAnxiety, Substance Abuse, PTSDDrug discovery – in-vitro data H1 CY2023 University of Western Australia

Partnerships with leading clinicians and formulation experts

The Market | Unmet Medical Need Continues to Grow

Over 700 million people are affected globally with some sort of mental illness, eg: depression, anxiety, PTSD, addiction or eating disorder

Source: The World Health Organisation

Global economic costs due to mental heath disorders estimated to be USD$800 Billion direct and US$1.7 Billion indirect

Source: National Centre for Biotechnology Information


25% of adults in the world will be affected by mental or neurological disorders at some point in their lives

Source: World Health Organisation

ACN: 651 290 729

Address: Suite 301, 10 Bridge St, Sydney NSW 2000 Australia